Foresight regarding Drug Candidates Acting on the Succinate–GPR91 Signaling Pathway for Non-Alcoholic Steatohepatitis (Nash) Treatment

The authors describe the mechanism of the succinate–GPR91 signaling pathway in NASH and summarize the drugs that act on this pathway, with the aim of providing a new approach to NASH treatment.
[Biomedicine & Pharmacotherapy]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Matrix Metalloproteinase-9 Inhibition or Deletion Attenuates Portal Hypertension in Rodents

Liver SMAD2 phosphorylation was down-regulated in all series with matrix metalloproteinase (MMP) inhibition or knock-out, and MMP-9 inhibition or deletion ameliorated the severity of cirrhosis, portal hypertension, and associated derangements.
[Journal of Cellular and Molecular Medicine]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Targeting Epigenetically Maladapted Vascular Niche Alleviates Liver Fibrosis in Nonalcoholic Steatohepatitis

Investigators used multiomics analysis of human cirrhotic liver, a Western diet – and carbon tetrachloride – induced minipig nonalcoholic steatohepatitis model, and genetically modified mice to unravel the landscape of the vascular adaptome at the single-cell level, in which endothelial cells and TH17 cells jointly contributed to liver cirrhosis.
[Science Translational Medicine]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Poxel Completes Enrollment in Phase II NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven Patients

POXEL SA announced the completion of enrollment in DESTINY-1, a dose-ranging Phase II trial evaluating PXL065 for the treatment of non-alcoholic steatohepatitis (NASH).
[POXEL SA]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Conditioned Medium from Stem Cells Derived from Human Exfoliated Deciduous Teeth Ameliorates NASH via the Gut-Liver Axis

The authors examined the benefits of serum-free conditioned medium from stem cells derived from human exfoliated deciduous teeth on a murine non-alcoholic steatohepatitis (NASH) model induced by a combination of Western diet and repeated administration of low doses of carbon tetrachloride intraperitoneally, focusing on the gut-liver axis.
[Scientific Reports]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Neutrophil Extracellular Traps in Patients with Liver Cirrhosis and Hepatocellular Carcinoma

Plasma markers of neutrophil extracellular traps formation were elevated in liver cirrhosis and correlated to the degree of liver dysfunction in patients with liver cirrhosis and/or hepatocellular carcinoma.
[Scientific Reports]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Yiguanjian Decoction Inhibits Macrophage M1 Polarization and Attenuates Hepatic Fibrosis Induced by CCl4/2-AAF

In vitro, RAW264.7 cells were treated with lipopolysaccharides to induce macrophage polarization to the M1 phenotype, and they were co-cultured with WB-F344 cells and allocated to M group, YGJ group and WIF-1 group with untreated cells as control.
[Pharmaceutical Biology]
[zotpress userid=” items=’K6ZW357K’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

4210 da and 1866 da Polypeptides as Potential Biomarkers of Liver Disease Progression in Hepatitis B Virus Patients

New biochemical serum markers could be used to advance the diagnosis and prognosis of HBV-associated liver diseases during the progression of chronic hepatitis B into cirrhosis and hepatocellular carcinoma. Scientists determined whether the 4210 Da and 1866 Da polypeptides are serum metabolite biomarkers of hepatopathy with hepatitis B virus.
[Scientific Reports]
[zotpress userid=” items=’AIARR7BU’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Galecto Announces First Patient Treated in Phase IIa Trial of the Oral LOXL2 Inhibitor GB2064 in Myelofibrosis (the MYLOX-1 Trial)

Galecto, Inc. announced the treatment of the first patient in a Phase IIa trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis. The current standard of care for myelofibrosis is JAK inhibitors, but questions remain regarding side effects caused by the mechanism of action.
[Galecto, Inc.]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Co-encapsulation of Collagenase Type I and Silibinin in Chondroitin Sulfate Coated Multilayered Nanoparticles for Targeted Treatment of Liver Fibrosis

Investigators demonstrated that chondroitin sulfate coated multilayered 50-nm nanoparticles encapsulating collagenase and silibinin broke down the dense collagen stroma, while silibinin inhibited activated hepatic stellate cells.
[Carbohydrate Polymers]
[zotpress userid=” items=’3442VQJP’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Versantis Announces Positive Phase Ib Results for VS-01 in Patients with Decompensated Cirrhosis

Versantis announced positive results from a Phase Ib clinical trial of VS-01 in decompensated liver cirrhosis. VS-01 was found to be safe and well tolerated in this first-in-human, single ascending and multiple dose study led by Prof. Dr. Jonel Trebicka at the Goethe University Hospital Frankfurt.
[Versantis]
[zotpress userid=’6606345′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share
Share